Company Overview
| Stock Name | 中國先鋒醫藥控股有限公司 |
|---|---|
| Stock Code | 01345 |
| Company Full Name | 中國先鋒醫藥控股有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事營銷及推廣進口醫藥產品及醫療器械，以及提供相關渠道管理服務。 |
| Listing Date | 2013-11-05 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市普陀區武威路88弄15號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.pioneer-pharma.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 4.10 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 410,008,200 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 3.84 |
|---|---|
| First Day Open | HK$ 3.9 |
| First Day Change | 1.52% |
| First Day Volume | 113966000.0 |
| First Day Turnover | 441414000.0 |
Use of Proceeds
| Use of Proceeds | 1、約30%所得款項凈額或43180萬港幣，將用以繼續擴充我們的業務營運及提升我們的營銷、推廣及銷售能力； 2、約15%所得款項凈額或21590萬港幣，將用于升級現有及于湖北省建造新的物流及倉儲設施，以提升我們的倉儲能力及改善營運效率； 3、約5%所得款項凈額或7200萬港幣，將用于更換、改善及升級信息管理系統之硬件與軟件，以改善我們的管理及控制其推廣網絡及營運制造； 4、約25%所得款項凈額或35980萬港幣，將用于擴大產品組合； 5、約15%所得款項凈額或21590萬港幣，將用于海外供應商購入進口醫藥產品及醫療設備，以滿足不斷增長的需求； 6、約10%所得款項凈額或14390萬港幣，將用作我們的營運資金及其他一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (1)
UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (2)
UBS Securities Hong Kong Limited CE BIN466
星展亚洲融资有限公司 CE AAE430
Joint Lead Managers (2)
UBS Securities Hong Kong Limited CE BIN466
星展亚洲融资有限公司 CE AAE430
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 李新洲 |
|---|---|
| Company Secretary | 吳嘉雯 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李新洲及關連人士(67.16%) |
|---|
